Mortality at 1 year · bullous pemphigoid
It is very uncertain whether methylprednisolone plus azathioprine changes mortality at 1 year compared with methylprednisolone plus dapsone (very low certainty).
1 finding from 1 review
Quality of life ‐ not measured · bullous pemphigoid
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events at 1 year · bullous pemphigoid
1 finding from 1 review
Any known death after randomisation (fetal, neonatal, child, child as adult) · women at risk of preterm birth
It is very uncertain whether betamethasone acetate plus phosphate changes any known death after randomisation (fetal, neonatal, child, child… compared with betamethasone phosphate – fetal/neonatal outcomes (very low certainty).
1 finding from 1 review
Respiratory distress syndrome · women at risk of preterm birth
It is very uncertain whether betamethasone acetate plus phosphate changes respiratory distress syndrome compared with betamethasone phosphate – fetal/neonatal outcomes (very low certainty).
1 finding from 1 review
Intraventricular haemorrhage · women at risk of preterm birth
It is very uncertain whether betamethasone acetate plus phosphate changes intraventricular haemorrhage compared with betamethasone phosphate – fetal/neonatal outcomes (very low certainty).
1 finding from 1 review
Necrotising enterocolitis · women at risk of preterm birth
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Chronic lung disease · women at risk of preterm birth
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
ADHD symptoms · Children and adolescents with ADHD
It is very uncertain whether methylphenidate changes ADHD symptoms: all parallel‐group trials and first‐period cross‐over… compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Proportion of participants with one or more serious adverse events · Children and adolescents with ADHD
It is very uncertain whether methylphenidate changes proportion of participants with one or more serious adverse events compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Adverse events considered non‐serious (penicillin versus doxycycline) · Children and adolescents with ADHD
It is very uncertain whether methylphenidate changes proportion of participants with one or more adverse events… compared with placebo or no intervention (very low certainty).
1 finding from 1 review
General behaviour: all parallel‐group trials and first‐period cross‐over trials General behaviour rating scales (Teacher‐rated) · Children and adolescents with ADHD
It is very uncertain whether methylphenidate changes general behaviour: all parallel‐group trials and first‐period… compared with placebo or no intervention (very low certainty).
1 finding from 1 review
QoL · Children and adolescents with ADHD
It is very uncertain whether methylphenidate changes quality of life (parent‐rated) compared with placebo or no intervention (very low certainty).
1 finding from 1 review
All‐cause mortality up to 120 days · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical improvement: discharged alive ‐ not reported · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28 · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events ‐ not reported · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events ‐ not reported · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hospital‐acquired infections ‐ not reported · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Invasive fungal infections ‐ not reported · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found